MIND MEDICINE (MINDMED) INC. Mind Medicine (MindMed) Inc. Stock Deutsche Boerse AG
Equities
MMQ
CA60255C8850
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.375 EUR | -10.38% |
|
-12.30% | +147.49% |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 628M 591M |
|---|---|---|---|---|---|
| Net income 2024 * | -94M -88.37M | Net income 2025 * | -106M -99.65M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 184M 173M | Net cash position 2025 * | 99.5M 93.54M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-5.61
x | P/E ratio 2025 * |
-6.07
x | Employees | 57 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mind Medicine (MindMed) Inc.
More recommendations
More press releases
More news
| 1 day | -10.38% | ||
| 1 week | -12.30% | ||
| Current month | -2.16% | ||
| 1 month | -9.26% | ||
| 3 months | +144.03% | ||
| 6 months | +211.34% | ||
| Current year | +147.49% |
1 week
8.38
9.47
1 month
8.3812.03
Current year
3.2112.03
1 year
2.2212.03
3 years
1.9675.00
5 years
1.9675.00
10 years
1.9675.00
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Barrow
CEO | Chief Executive Officer | - | 21-01-13 |
Schond Greenway
DFI | Director of Finance/CFO | 52 | 22-05-22 |
Miri Wernli
PSD | President | 71 | 20-02-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andreas Krebs
BRD | Director/Board Member | 66 | 21-09-28 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 22-08-10 |
David Gryska
BRD | Director/Board Member | 68 | 23-06-20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 8.85 | -5.30% | 0 |
| 24-04-17 | 9.345 | -0.53% | 2,065 |
| 24-04-16 | 9.395 | -0.74% | 50 |
| 24-04-15 | 9.465 | +3.90% | 1,273 |
| 24-04-12 | 9.11 | -4.61% | 1,413 |
Delayed Quote Deutsche Boerse AG, April 18, 2024 at 02:46 pm EDT
More quotes
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Calendar
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
8.91
USD
Average target price
30.86
USD
Spread / Average Target
+246.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.82% | 41.35B | |
| +44.25% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- MNMD Stock
- MMQ Stock
